http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Jul 2026 14:32:19 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Plains+All+American+Pipeline+%28PAA%29+spreader+of+9570+contracts+of+November+23+and+January+27+calls/26807441.html <p>Plains All American Pipeline (NASDAQ: PAA) 30-day call option implied volatility is 21; compared to its 52-week range of 14 to 25 with a focus on a spreader of 9570 contracts of November 23 and January 27 calls. </p> http://www.streetinsider.com/Options/Plains+All+American+Pipeline+%28PAA%29+spreader+of+9570+contracts+of+November+23+and+January+27+calls/26807441.html Thu, 23 Jul 2026 14:32:19 -0400 PAA http://www.streetinsider.com/Analyst+PT+Change/Plains+All+American+%28PAA%29+PT+Raised+to+%2423+at+RBC+Capital/26792286.html RBC Capital analyst Elvira Scotto raised the price target on Plains All American (NASDAQ: PAA) to $23.00 (from $21.00) while maintaining a Sector Perform rating. http://www.streetinsider.com/Analyst+PT+Change/Plains+All+American+%28PAA%29+PT+Raised+to+%2423+at+RBC+Capital/26792286.html Tue, 21 Jul 2026 07:44:54 -0400 PAA http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/Press+Releases/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html <div class="xn-content"> <ul type="disc"><li><b>250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far</b></li><li><b>Anticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027</b></li><li><b>Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program</b></li><li><b>Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network</b></li><li><b>Participants now progressing through the planned 36-week randomised treatment period</b></li></ul><p id="temp_ReleaseStart"><span class="legendSpanClass"><location value="LU/au..melbou" idsrc="xmltag.org" >MELBOURNE, Australia</location></span>, <span class="legendSpanClass"><chron>16 July 2026</chron></span> /PRNewswire/ -- Neurizon® <span>Therapeutics Limited</span> (ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical http://www.streetinsider.com/PRNewswire/HEALEY+ALS+Platform+Trial+Regimen+I+enrolment+completed+-+Topline+results+for+NUZ-001+accelerated+to+Q2+CY2027/26781031.html Thu, 16 Jul 2026 23:48:00 -0400 A.31368885 NUZ NUZTF O.00756621 O.49918125 PAA http://www.streetinsider.com/Analyst+PT+Change/Plains+All+American+%28PAA%29+PT+Raised+to+%2423+at+Barclays/26775687.html Barclays analyst Theresa Chen raised the price target on Plains All American (NASDAQ: PAA) to $23.00 (from $21.00) while maintaining a Underweight rating. http://www.streetinsider.com/Analyst+PT+Change/Plains+All+American+%28PAA%29+PT+Raised+to+%2423+at+Barclays/26775687.html Thu, 16 Jul 2026 05:18:55 -0400 PAA http://www.streetinsider.com/Analyst+PT+Change/Plains+All+American+%28PAA%29+PT+Raised+to+%2425+at+Truist+Securities/26770785.html Truist Securities analyst Neal Dingmann raised the price target on Plains All American (NASDAQ: PAA) to $25.00 (from $23.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/Plains+All+American+%28PAA%29+PT+Raised+to+%2425+at+Truist+Securities/26770785.html Wed, 15 Jul 2026 07:10:34 -0400 PAA http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html <p>Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).</p><p>The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.</p><p>Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.</p><p>For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html Fri, 10 Jul 2026 11:22:43 -0400 AM KMI LNG MPLX OKE PAA SUN TRGP VG WMB http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html <p>Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).</p><p>The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.</p><p>Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.</p><p>For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html Fri, 10 Jul 2026 11:22:43 -0400 AM KMI LNG MPLX OKE PAA SUN TRGP VG WMB http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html <p>Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).</p><p>The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.</p><p>Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.</p><p>For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html Fri, 10 Jul 2026 11:22:43 -0400 AM KMI LNG MPLX OKE PAA SUN TRGP VG WMB http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html <p>Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).</p><p>The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.</p><p>Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.</p><p>For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html Fri, 10 Jul 2026 11:22:43 -0400 AM KMI LNG MPLX OKE PAA SUN TRGP VG WMB http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html <p>Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).</p><p>The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.</p><p>Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.</p><p>For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html Fri, 10 Jul 2026 11:22:43 -0400 AM KMI LNG MPLX OKE PAA SUN TRGP VG WMB http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html <p>Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).</p><p>The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.</p><p>Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.</p><p>For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html Fri, 10 Jul 2026 11:22:43 -0400 AM KMI LNG MPLX OKE PAA SUN TRGP VG WMB http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html <p>Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).</p><p>The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.</p><p>Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.</p><p>For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html Fri, 10 Jul 2026 11:22:43 -0400 AM KMI LNG MPLX OKE PAA SUN TRGP VG WMB http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html <p>Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).</p><p>The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.</p><p>Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.</p><p>For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html Fri, 10 Jul 2026 11:22:43 -0400 AM KMI LNG MPLX OKE PAA SUN TRGP VG WMB http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html <p>Investing.com -- Wells Fargo issued its second quarter 2026 earnings preview for midstream energy companies, recommending investors hold Plains All American Pipeline (NYSE:PAA) and Targa Resources (NYSE:TRGP) heading into the reporting period while avoiding Williams Companies (NYSE:WMB).</p><p>The bank expects another positive earnings season overall. Wells Fargo forecasts Cheniere Energy (NYSE:LNG), ONEOK (NYSE:OKE), Sunoco (NYSE:SUN), Targa Resources, and Viper Energy Partners (NASDAQ:VG) to exceed consensus estimates.</p><p>Keyera (TSX:KEY) and MPLX (NYSE:MPLX) could miss expectations, according to the preview.</p><p>For Cheniere Energy and Cheniere Energy Partners, Wells Fargo points to higher international spreads and volumes, along with a lighter maintenance cycle suggesting lower operating http://www.streetinsider.com/General+News/Wells+Fargo+previews+Q2+midstream+earnings%2C+favors+PAA+and+TRGP/26756277.html Fri, 10 Jul 2026 11:22:43 -0400 AM KMI LNG MPLX OKE PAA SUN TRGP VG WMB